Charles River Laboratories International (CRL) Részvény Árfolyam
Charles River Laboratories International Árfolyam
Az elmúlt 19 évben a(z) Charles River Laboratories International árbevétele évi 7,3%-kal nőtt, és elérte a 4,02 Md USD-t. Az egy részvényre jutó eredmény évi 13,1%-kal csökkent az elmúlt 17 évben. A(z) Charles River Laboratories International esetében a -3,6%-os nettó árrés csökkent a néhány évvel ezelőtti 11,0%-hoz képest. A(z) Charles River Laboratories International 12 hónapos konszenzusos célára 273,00 USD, körülbelül alatt az árfolyamot 18,0%-kal. 23 elemzőből 18 vételt javasol — az összesített konszenzus Vétel.
Charles River Laboratories International részvényár
Ezeket az adatokat az Eulerpool API-n keresztül
100 000 kérés/hó ingyen · nincs bankkártya
Charles River Laboratories International üzleti modell és részvényelemzés
Gyakran feltett kérdések a Charles River Laboratories International részvényről
The business model of Charles River Laboratories International Inc primarily revolves around providing research and development (R&D) solutions and services to the pharmaceutical, biotechnology, and medical device companies. As a leading contract research organization (CRO), the company offers a wide range of preclinical and clinical laboratory services, including safety assessment, discovery support, manufacturing support, and laboratory animal research services. Charles River Laboratories operates on a fee-for-service basis, collaborating with its clients to accelerate drug discovery, development, and commercialization processes. With a focus on quality, reliability, and scientific expertise, the company aims to support its clients in advancing their scientific research and achieving their business goals.
Charles River Laboratories International Inc is primarily active in the life sciences industry.
Some of the main competitors of Charles River Laboratories International Inc in the market include Covance Inc., Envigo, PPD, Eurofins Scientific, and LabCorp.
Charles River Laboratories International Inc is a renowned company in the field of preclinical and clinical laboratory services. Founded in 1947, Charles River has built a strong reputation as a trusted provider of comprehensive research support. With a focus on helping pharmaceutical and biotechnology companies bring new drugs to market, they offer a wide range of services including drug discovery, safety assessment, and manufacturing support to clients worldwide. The company's expertise in advanced animal models, laboratory sciences, and support services has propelled it to the forefront of the life sciences industry. Today, Charles River Laboratories continues to play a vital role in advancing much-needed medical therapies.
Charles River Laboratories International Inc has achieved several significant milestones. It has consistently demonstrated strong financial performance, delivering consistent revenue growth and expanding its global footprint. The company has successfully completed strategic acquisitions, enabling it to enhance its capabilities and expand its service offerings. Charles River Laboratories International Inc has also received notable recognition, including being named one of the World's Most Ethical Companies for several consecutive years. Moreover, the company has been at the forefront of scientific advancements, collaborating with global pharmaceutical and biotechnology companies to develop innovative solutions that improve drug discovery and development processes.
Charles River Laboratories International Inc is primarily present in the following countries and regions: United States, Canada, Europe, Asia Pacific, and Latin America.
Charles River Laboratories International Inc represents various values and corporate philosophies. The company is committed to their mission of improving the lives of people and animals through innovative research and development. They aim to maintain the highest standards of scientific integrity, ethical conduct, and regulatory compliance. Charles River Laboratories prioritizes collaboration and partnership with their clients to provide comprehensive solutions and exceptional service. With a focus on quality, efficiency, and expertise, they strive to consistently deliver reliable and innovative scientific services and products. Through their dedication to responsible and sustainable practices, Charles River Laboratories aims to make a positive impact on society and the environment.
Az elemzők jelenleg 267,60 USD átlagos célárat adnak a Charles River Laboratories International részvényre (medián: 273,00 USD), ami -15,2 % a legutóbbi árhoz képest. A konszenzus 23 elemzői minősítésen alapul.
Charles River Laboratories International Elemzői célárfolyamok 2026
23 elemző értékeli jelenleg a Charles River Laboratories International részvényt: 18 vételt, 5 tartást és 0 eladást javasol. 2026-re az elemzők 3,92 Md USD árbevételt és 11,46 USD EPS-t várnak a Charles River Laboratories International esetében.
Charles River Laboratories International Elemzői célárfolyamok 2026
Az aktuális árfolyamon a Charles River Laboratories International részvény 296,67 EUR (333,05 USD).
A Charles River Laboratories International részvény (CRL) 6 tőzsdén jegyzett, többek között: NYSE (CRL), SIX (Zürich) (RV6.SW), XETRA (RV6.DE), Frankfurt (RV6.F), München (RV6.MU), Düsseldorf (RV6.DU).
Charles River Laboratories International Inc is a global leader in the field of life sciences, offering its customers a wide range of products and services. The company's business model is based on three main areas: research and development, preclinical services, and bioproducts. Research and Development: Charles River Laboratories offers a variety of services to support its customers in the development of new products. These include chemical and pharmacological screening systems, study design and planning, cell and tissue banking, genotoxicology, protein and antibody production, and much more. Charles River Laboratories has a comprehensive range of scientific and technical capabilities to assist its customers in the development of new drugs, biotechnology products, and medical devices. Preclinical Services: The company provides its customers with a wide range of preclinical services to test the safety and efficacy of products. These services include toxicology, pathology, pharmacology, bioanalytics, and clinical diagnostics. Charles River Laboratories has several preclinical research facilities worldwide and can support customers in the validation of new therapies and products. Bioproducts: Charles River Laboratories produces a variety of bioproducts for research and development, including cell lines, antibodies, nucleic acids, and proteins. The company also offers specialized services such as genetic manipulation and custom modification of cell lines to achieve specific research goals. The company focuses on customer loyalty and has earned the trust of customers by offering high-quality products and services. Charles River Laboratories has a global presence with facilities in North America, Europe, and Asia, and can serve customers worldwide. The company also maintains a strong partnership with the scientific community by supporting research initiatives and public health measures. Charles River Laboratories is committed to offering its customers a comprehensive range of services to meet their needs in the field of life sciences. The company is dedicated to continuously improving its research and development and introducing new services and products to meet the ever-changing needs of customers.
A várható bevétele Charles River Laboratories International 3,92 Md USD. Ez az érték az aktuális pénzügyi adatokon alapul, és a vállalat üzleti teljesítményét tükrözi.
A várható nyeresége Charles River Laboratories International 563,83 M USD. A nettó nyereség a vállalat nyereségességét tükrözi az összes költség levonása után.
A Charles River Laboratories International ár/nyereség mutatója (P/E) jelenleg 29,07. A P/E mutató az aktuális részvényárat az egy részvényre jutó nyereséggel hasonlítja össze, és segít a befektetőknek a Charles River Laboratories International részvény értékelésének megértésében.
A Charles River Laboratories International ár/értékesítés mutatója (P/S) jelenleg 4,19. A P/S mutató a piaci kapitalizációt az éves bevételhez hasonlítja, és a Charles River Laboratories International részvény értékelési mérőszámaként szolgál.
Az Eulerpool minőségi pontszáma a Charles River Laboratories International számára 3/10.
A Charles River Laboratories International ISIN-je US1598641074. Az ISIN (International Securities Identification Number) a nemzetközi securities azonosító.
A Charles River Laboratories International WKN-je 939391. A WKN (Wertpapierkennnummer) egy hatjegyű német értékpapír-azonosító szám.
A Charles River Laboratories International ticker-e CRL. A ticker szimbólum a Charles River Laboratories International részvény tőzsdei kereskedésénél használatos.
Charles River Laboratories International részvény
Charles River Laboratories International Peer Group
Charles River Laboratories International Tőzsdei rövidítés
Charles River Laboratories International FIGI
A Charles River Laboratories International összes alapfundamentuma és mélyreható elemzése
A Charles River Laboratories International részvény Eulerpool-elemzése olyan fontos pénzügyi mutatókat tartalmaz, mint a bevétel, nyereség, P/E arány, P/S arány, EBIT, valamint információk az osztalékról. Vizsgáljuk a részvények, piaci kapitalizáció, adósság, saját tőke és kötelezettségek vonatkozásait is Charles River Laboratories International. Ha részletesebb információt keres ezekről a témákról, részletes elemzéseket kínálunk az aloldalainkon.